GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torii Pharmaceutical Co Ltd (TSE:4551) » Definitions » Capex-to-Revenue

Torii Pharmaceutical Co (TSE:4551) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Torii Pharmaceutical Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Torii Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2024 was 円0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was 円13,451.00 Mil.

Hence, Torii Pharmaceutical Co's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


Torii Pharmaceutical Co Capex-to-Revenue Historical Data

The historical data trend for Torii Pharmaceutical Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Torii Pharmaceutical Co Capex-to-Revenue Chart

Torii Pharmaceutical Co Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 -

Torii Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Torii Pharmaceutical Co's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Torii Pharmaceutical Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Torii Pharmaceutical Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Torii Pharmaceutical Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Torii Pharmaceutical Co's Capex-to-Revenue falls into.



Torii Pharmaceutical Co Capex-to-Revenue Calculation

Torii Pharmaceutical Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-216) / 54637
=0.00

Torii Pharmaceutical Co's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 13451
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Torii Pharmaceutical Co  (TSE:4551) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Torii Pharmaceutical Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Torii Pharmaceutical Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Torii Pharmaceutical Co (TSE:4551) Business Description

Traded in Other Exchanges
N/A
Address
Torii Nihonbashi Buildingg, 4-1, Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo, JPN, 103-8439
Torii Pharmaceutical Co Ltd is a major drug manufacturing company. The company utilizes strategic partnerships with other pharmaceutical companies in order to combine research and marketing functions. Torii's key therapeutic areas include renal diseases, hemodialysis, HIV, skin diseases, and allergens. The vast majority of the company's net mainstay product sales are derived from the renal diseases and hemodialysis operations, followed by HIV. Torii's places its strategic focus on prompt market penetration and expansion of new products as well as maximizing values of mainstay products in each priority area.

Torii Pharmaceutical Co (TSE:4551) Headlines

No Headlines